Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women

被引:8
|
作者
Lian, Jing [1 ,2 ]
Xu, En-Wei [1 ]
Xi, Yan-Feng [1 ]
Wang, Hui-Wen [1 ]
Bu, Peng [1 ]
Wang, Jin-fen [1 ]
Wang, Li-Xia [1 ]
机构
[1] Shanxi Prov Canc Hosp, Dept Pathol, Taiyuan, Shanxi, Peoples R China
[2] Shanxi Med Univ, Inst Forens Med, Taiyuan, Shanxi, Peoples R China
关键词
PIK3CA; ARMS; clinicopathologic characteristics; breast cancer; Chinese; COMPLETE RESPONSE; POOR-PROGNOSIS; PTEN; HER2; RESISTANCE; LAPATINIB; PATHWAY; RATES;
D O I
10.1177/1533033820950832
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Mutations of PIK3CA have recently been shown to play an important role in the pathogenesis and progression of breast neoplasms. The prevalence of PIK3CA in Chinese breast cancer patients may be underestimated. Therefore, we investigated the distribution of somatic PIK3CA mutation in Chinese breast cancer patients and explored their role in tumor phenotypes. Methods: Mutational analysis of PIK3CA was done in 113 primary breast cancers of Chinese women used Amplification refractory mutation system (ARMS). The relationship of PIK3CA mutations with several clinicopathologic characteristics was analyzed. Results: PIK3CA gene mutation was identified in 43(38.05%) cases and has a more significant difference between exon 9 and 20. HER2 gene amplification was 32.6% in 43 cases of PIK3CA mutation, but 37.1% in 70 cases of non-mutation (chi(2)= 0.245, P > 0.05). There was no significant correlation of the age distribution, lymph node status, histological tumor grading, ER and/or PR and P53 between 2 groups (P > 0.05). Conclusion: A high frequency of somatic PIK3CA mutation was detected in Chinese breast cancer patients, especially in exon 20. The relationship between PIK3CA gene mutation and clinical pathological features of breast cancer needs to be further studied in a large series of patients. PIK3CA mutations seem to have the potential to be used in target treatment and as an indicator of prognosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
    E. Razis
    M. Bobos
    V. Kotoula
    A. G. Eleftheraki
    H. P. Kalofonos
    K. Pavlakis
    P. Papakostas
    G. Aravantinos
    G. Rigakos
    I. Efstratiou
    K. Petraki
    D. Bafaloukos
    I. Kostopoulos
    D. Pectasides
    K. T. Kalogeras
    D. Skarlos
    G. Fountzilas
    Breast Cancer Research and Treatment, 2011, 128 : 447 - 456
  • [32] The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis
    Charla C. Engels
    Mandy Kiderlen
    Esther Bastiaannet
    Ronald van Eijk
    Antien Mooyaart
    Vincent T. H. B. M. Smit
    Anton J. M. de Craen
    Peter J. K. Kuppen
    Judith R. Kroep
    Cornelis J. H. van de Velde
    Gerrit Jan Liefers
    Breast Cancer Research and Treatment, 2016, 156 : 361 - 370
  • [33] The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions
    Cho, Young-Bin
    Park, Kyoung-Sik
    MEDICINA-LITHUANIA, 2025, 61 (03):
  • [34] PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients
    Mangone, Flavia R.
    Bobrovnitchaia, Irina G.
    Salaorni, Sibeli
    Manuli, Erika
    Nagai, Maria A.
    CLINICS, 2012, 67 (11) : 1285 - 1290
  • [35] An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
    Jank, Paul
    Karn, Thomas
    van Mackelenbergh, Marion
    Lindner, Judith
    Treue, Denise
    Huober, Jens
    Engels, Knut
    Solbach, Christine
    Diebold, Kurt
    Marme, Frederik
    Mueller, Volkmar
    Schneeweiss, Andreas
    Sinn, Hans-Peter
    Fehm, Tanja
    Schem, Christian
    Stickeler, Elmar
    Fasching, Peter
    Budczies, Jan
    Felder, Baerbel
    Nekljudova, Valentina
    Holtschmidt, Johannes
    Untch, Michael
    Denkert, Carsten
    Loibl, Sibylle
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3868 - 3880
  • [36] The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis
    Engels, Charla C.
    Kiderlen, Mandy
    Bastiaannet, Esther
    van Eijk, Ronald
    Mooyaart, Antien
    Smit, Vincent T. H. B. M.
    de Craen, Anton J. M.
    Kuppen, Peter J. K.
    Kroep, Judith R.
    van de Velde, Cornelis J. H.
    Liefers, Gerrit Jan
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (02) : 361 - 370
  • [37] Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells
    Dunn, Sianadh
    Lombardi, Olivia
    Lukoszek, Radoslaw
    Cowling, Victoria H.
    OPEN BIOLOGY, 2019, 9 (04)
  • [38] PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis
    Liu, Yi-Rong
    Jiang, Yi-Zhou
    Zuo, Wen-Jia
    Yu, Ke-Da
    Shao, Zhi-Ming
    ONCOTARGETS AND THERAPY, 2014, 7 : 543 - 552
  • [39] PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast
    Li, Hua
    Zhu, Rong
    Wang, Lei
    Zhu, Tengfang
    Li, Qiong
    Chen, Qi
    Wang, Hong
    Zhu, Hongguang
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2010, 88 (01) : 150 - 155
  • [40] PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis
    Fan, Hongwei
    Li, Chao
    Xiang, Qian
    Xu, Ling
    Zhang, Zhuo
    Liu, Qianxin
    Zhang, Tonttong
    Zhou, Ying
    Zhao, Xia
    Cui, Yimin
    THORACIC CANCER, 2018, 9 (05) : 571 - 579